A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study (NCT01311687), a randomized phase 3 study. The primary outcome is Progression-free Survival (PFS) - Primary Analysis.

2. Clinical Question

3. Trial Design

This was a phase 3, randomized, open-label, parallel-group study. The registry record lists enrollment of 455 participants: 302 in the pomalidomide plus low-dose dexamethasone group and 153 in the high-dose dexamethasone group for the primary progression-free survival analysis. The study was sponsored by Celgene and is recorded as completed. Its start date was 2011-03-11, and its primary completion date was 2013-03-01.

Randomization assigns participants to treatment groups by chance, which is intended to support a fair comparison of outcomes. Parallel-group design means that each participant was assigned to a treatment group rather than receiving both study regimens as a planned sequence. Open-label means that masking was not used. The registry record does not report further details about allocation procedures or any steps taken to reduce bias in outcome assessment beyond describing independent adjudication of progression for the primary endpoint.

The regimens differed in both the drugs used and the schedule of dexamethasone. The intervention group received pomalidomide with low-dose dexamethasone; the comparator received high-dose dexamethasone. Both treatment descriptions state that therapy continued until disease progression. The recorded primary endpoint was progression-free survival, with overall survival and additional response, progression, and safety outcomes listed among the secondary outcomes.

The registry record describes the primary analysis population as intent-to-treat. It does not report the original sample-size justification, the planned number of events, or the complete statistical analysis plan. Nor does it report whether interim analyses were planned. The record’s planning illustrations based on observed effects are separate from the trial’s original design assumptions and cannot establish what assumptions informed the enrollment target.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Participants were randomized in a 2:1 ratio. Treatment phase discontinuation occurred when a participant had confirmed progressive disease. Participants who did not progress but who were intolerant to treatment, or no longer wished to receive study treatment entered the progression-free survival (PFS) follow-up period until disease progression.

Treatment Phase

PFS Follow-up Phase

Analysis population for the primary outcome, as defined in the registry: Intent-to-treat population

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Intent-to-treat population (all participants who were randomized, regardless of whether they received study treatment or not)

6. Primary Endpoint

The registry lists the primary outcome as Progression-free Survival (PFS) - Primary Analysis, measured over From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks..

Progression-free survival measures the time from randomization until disease progression or death on study, whichever occurs first. In this trial, progression was assessed by the Independent Response Adjudication Committee using International Myeloma Working Group Uniform Response criteria. The registry describes progression criteria involving increases from nadir in serum M-component, urine M-component, or bone marrow plasma cell percentage; new or enlarging bone lesions or soft tissue plasmacytomas; or hypercalcemia attributed solely to plasma cell proliferative disease.

Time-to-event endpoints are useful when the event can occur at different times and not every participant necessarily has an event observed by the data cut-off. They incorporate both the timing of recorded events and the follow-up information available for participants who have not yet had an event. The reported median gives a time-point summary, while a hazard ratio summarizes the relative event hazard over the observed follow-up under the analysis method.

The primary analysis used data from randomization through the data cut-off date of 07 September 2012; the maximum duration of follow-up for progression-free survival assessments was 57 weeks. The registry reports median progression-free survival of 15.7 weeks for pomalidomide plus low-dose dexamethasone and 8.0 weeks for high-dose dexamethasone. The comparison was reported as a hazard ratio of 0.45, with a 95% confidence interval from 0.35 to 0.59 and p < 0.001. These summaries describe the observed trial data; they do not by themselves explain the biological pathway or predict an individual participant’s outcome.

7. Results Posted in the Registry

• Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone: hazard ratio 0.45 (95% CI 0.35–0.59), reported p < 0.001 (as reported in the registry).

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Overall Survival - Primary Analysis

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Log Rank); it was not recalculated.
• Result:
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone: hazard ratio 0.53 (95% CI 0.37–0.74), reported p < 0.001 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval excludes no difference (a ratio of 1), so the hazard of the event is statistically lower for Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Overall Survival With a Later Cut-off Date

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Log Rank); it was not recalculated.
• Result:
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone: hazard ratio 0.70 (95% CI 0.54–0.92), reported p = 0.009 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval excludes no difference (a ratio of 1), so the hazard of the event is statistically lower for Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Overall Survival Based on the Final Dataset

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Log Rank); it was not recalculated.
• Result:
  • Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone: hazard ratio 0.74 (95% CI 0.60–0.91), reported p = 0.005 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval excludes no difference (a ratio of 1), so the hazard of the event is statistically lower for Pomalidomide Plus Low-Dose Dexamethasone vs High-Dose Dexamethasone than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The posted secondary outcomes cover overall survival at multiple data cut-offs, objective response under different response criteria, time to progression, time to response, and adverse events. The reported overall survival comparisons point in the same direction as the primary PFS comparison, with hazard ratio estimates below the equal-hazard reference and reported p-values below 0.05. The response and other secondary outcomes broaden the description of disease response and follow-up, but they address different questions from the primary endpoint.

The overall survival analyses are related to the primary result because they compare the same randomized groups and concern another time-to-event outcome. They are not interchangeable with progression-free survival: death is the event for overall survival, while the primary endpoint includes progression or death. Later overall survival analyses also use later data cut-offs, so they incorporate additional follow-up rather than serving as independent trials.

Secondary results generally carry less confirmatory weight when many outcomes or analyses are examined without a reported adjustment for multiple testing. Each additional test creates another opportunity for a seemingly notable result to arise by chance. The registry lists 24 outcome measures, 8 analyses, and 22 posted secondary outcomes, but does not report a multiplicity-control strategy. The reported secondary p-values should therefore be read as endpoint-specific evidence, not as proof that all secondary findings meet a single confirmatory standard.

Differences in endpoint definitions and analysis methods also matter. The response outcomes use distinct criteria, and the timing-based outcomes rely on follow-up. A pattern of results can add context to the primary finding, but does not resolve missing methodological information or eliminate uncertainty about secondary analyses. The registry record does not report a complete analysis plan that would establish which secondary outcomes were prespecified as confirmatory, how their testing order was set, or how missing data were handled across them.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Number of Participants With Adverse Events (AEs)
• Overall Survival - Primary Analysis
• Overall Survival With a Later Cut-off Date
• Overall Survival Based on the Final Dataset
• Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria
• Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria
• Time to Progression
• Time to Response

9. Statistical Interpretation

10. Statistical Methods Explained

The primary endpoint is a time-to-event outcome, so the analysis must account for both event timing and follow-up that ends before an event is observed. The registry reports median progression-free survival for each group and a hazard ratio comparing the groups. These are complementary summaries: the medians describe the central timing of the event process, while the hazard ratio compares event hazards across follow-up. Neither summary alone gives the full event-time distribution.

What does a hazard ratio summarize?

In general, a hazard is the instantaneous rate at which an event occurs among participants who remain event-free up to a given time. A hazard ratio compares that rate between groups over the analysis period. The registry-reported primary hazard ratio is 0.45 for pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone. A value below the equal-hazard reference indicates a lower estimated hazard in the first group under this comparison. A hazard ratio is not an absolute risk difference, and it does not say how many weeks an individual participant will live without progression.

A hazard ratio is also not a direct comparison of the group medians. The primary medians are 15.7 weeks and 8.0 weeks, but those values should be interpreted as separate time-to-event summaries, not used to reconstruct the hazard ratio. A single hazard ratio can compress a changing pattern over time into one estimate. The registry record does not report whether the proportional-hazards assumption was assessed or whether the relative hazards were expected to remain constant over follow-up.

How does the log-rank method contribute?

The registry identifies a Stratified Log Rank Test for the primary comparison. In general, the log-rank test compares the observed pattern of event timing between groups across follow-up. A stratified version performs that comparison within strata and combines information across them. The registry record does not report which factors defined the strata, so no particular stratification variables can be inferred. The p-value is evidence about compatibility between the observed data and a statistical null hypothesis under the test’s assumptions; it is not the probability that the null hypothesis is true, nor a measure of clinical importance.

The registry reports p < 0.001 for the primary comparison. The confidence interval for the hazard ratio describes uncertainty in the estimated relative hazard under the analysis. It provides a range of values compatible with the data and the method at the stated confidence level, rather than a range that contains a fixed proportion of individual participants’ outcomes. The interval from 0.35 to 0.59 is the reported 95% confidence interval.

What is censoring in a time-to-event analysis?

In general, a participant is censored when the event of interest has not been observed by the participant’s last available follow-up or the analysis cut-off. Censoring allows partial follow-up information to contribute without claiming that an event occurred at an unknown time. Valid interpretation depends on assumptions about how follow-up ends and how censoring relates to the event process. The registry provides the PFS data cut-off and maximum follow-up, but it does not report the number censored, reasons for censoring, or diagnostic checks of censoring assumptions.

The primary analysis is identified as intent-to-treat. In general, an intent-to-treat analysis compares participants according to their randomized groups, supporting preservation of the original randomization even when treatment exposure changes. The registry record does not detail how all post-randomization events, treatment discontinuations, or missing endpoint assessments were handled. Those particulars should not be inferred from the population label alone.

The overall survival analyses also use time-to-event methods. The primary overall survival analysis used the Log Rank method, as did the later cut-off and final-dataset analyses. Their hazard ratios, confidence intervals, p-values, and medians are reported with their corresponding cut-off dates. The primary overall survival analysis has a data cut-off of 07 September 2012; the later cut-off is 01 March 2013; the final dataset cut-off is 29 August 2017. These analyses use accumulating follow-up, so later estimates reflect more mature survival information and are not statistically independent of earlier estimates.

Response outcomes and safety outcomes differ from time-to-event endpoints and require their own analysis choices. The registry lists 24 outcome measures, 8 analyses, and 22 posted secondary outcomes. It does not provide enough detail in the record to establish the full method used for each secondary measure, the treatment of missing observations for those measures, or any adjustment across multiple statistical tests. The reported analyses are therefore best read in the context of the endpoint and method explicitly attached to each result.

11. Confidence Intervals and Precision

The primary hazard ratio is reported as 0.45, with a 95% confidence interval from 0.35 to 0.59. The interval communicates the statistical precision of the relative-hazard estimate: narrower intervals generally indicate more precision, while wider intervals leave more uncertainty about the magnitude. The reported interval lies below the equal-hazard reference, supporting the direction of the estimated comparison under the analysis method. It does not establish that every possible source of uncertainty or bias has been captured.

The group-specific medians are also accompanied by 95% confidence intervals. For pomalidomide plus low-dose dexamethasone, the median PFS is 15.7 weeks, with an interval from 13.0 to 20.1 weeks. For high-dose dexamethasone, the median is 8.0 weeks, with an interval from 7.0 to 9.0 weeks. These intervals describe uncertainty around each median estimate; they are not the same as a confidence interval for the difference between medians.

Confidence intervals should be interpreted alongside the point estimate, the endpoint definition, and the available follow-up. A confidence interval is not a guarantee that the true value lies inside its bounds. In general, it is a method-based range that reflects how estimates would vary across repeated studies under the model and assumptions. The registry record does not report every diagnostic assessment needed to judge those assumptions.

The later overall survival analyses have their own confidence intervals and cut-off dates. Longer follow-up can change both the amount of information and the estimate. The resulting intervals should therefore be compared with attention to the data cut-off and analysis population, not treated as though they arose from separate, unrelated trials. In particular, the final-dataset result is an update within the same trial rather than an independent confirmation.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning illustrations are based on the observed effect and are not the trial’s original design calculations. For the time-to-event outcomes, the figures represent total events, not participants per arm. The illustrations use a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation; each illustration considers an effect that is the stated fraction of the observed effect. The original trial design assumptions are not reported in the registry record.

The 80% power column describes the total number of events that a hypothetical planning calculation would require to have an 80% chance of detecting the specified effect under those assumptions. The 90% power column gives the event count for a higher chance of detecting that same effect. These are planning targets, not a description of the study’s achieved power. This is not observed power.

The rows consider the full observed effect and smaller fractions of that effect. Smaller effects are harder to distinguish from chance variation, so they require more events to reach the same target power under the stated planning approach. The displayed event counts rise as the assumed effect becomes smaller. For example, the primary PFS illustration lists 50 total events for 80% power when planning for 100% of the observed effect, and 197 total events when planning for 50% of the observed effect. The corresponding 90% power figures are 66 and 264 total events.

These calculations are illustrations for interpreting the observed effect, not a reconstruction of the original study’s enrollment target. They do not show that the trial had a particular probability of success, and they should not be substituted for the sponsor’s design rationale. No original sample-size justification or planned event target is reported in the registry record.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

d is the total number of events needed (Schoenfeld's formula) with 1:1 allocation and proportional hazards.

Worked calculation for this trial

1. Hazard ratio HR = 0.450, so ln(HR) = -0.7985.
2. d = 4 × (1.96 + 0.842)² / [ln(0.450)]² = 49.2, rounded up to 50 events in total for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
hr <- 0.45                              # observed hazard ratio
events_needed <- function(power, frac = 1) ceiling(round(4 * (z_a + qnorm(power))^2 / log(hr^frac)^2, 6))   # Schoenfeld, 1:1 allocation
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: events = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(events_needed(0.80, f), big.mark = ","), format(events_needed(0.90, f), big.mark = ",")))

# Simulation: given d total events under proportional hazards, events in the treatment arm are Binomial(d, hr / (1 + hr)).
# The score (log-rank type) statistic is (D1 - d / 2) / sqrt(d / 4).
set.seed(1311687)
d    <- events_needed(0.80)
reps <- 20000
D1 <- rbinom(reps, d, hr / (1 + hr))
z  <- (D1 - d / 2) / sqrt(d / 4)
cat(sprintf("Simulated power with %s events: %.3f (%d replicates)\n", format(d, big.mark = ","), mean(abs(z) > z_a), reps))

Output from running the code

100% of observed effect: events = 50 (80% power), 66 (90% power)
 75% of observed effect: events = 88 (80% power), 118 (90% power)
 50% of observed effect: events = 197 (80% power), 264 (90% power)
Simulated power with 50 events: 0.818 (20000 replicates)

The simulation uses the fact that, with d events in total and proportional hazards, the number of events in the treatment arm is binomial. It is an approximation that conditions on the total number of events, and it should land close to the target power.

14. Group-Sequential Design Analysis

Many time-to-event trials, especially in oncology, stop or report early when interim data are overwhelming, so a single fixed-sample number understates the real design problem. The calculation below is an illustrative group-sequential design built from this trial's posted control median and hazard ratio. The registry record does not state the planned number of looks or the spending function, so the design is a planning illustration, not a reconstruction of the protocol. Assumed: one-sided α = 0.025, 90% power, three equally spaced looks on information, Lan-DeMets O'Brien-Fleming spending, 24 months of accrual, 60 months in total and a 1% monthly dropout hazard.

Under these assumptions the design needs about 70 participants in total, with the boundaries below.

Fixed design versus group-sequential alternatives

Group-sequential designs cost a small increase in maximum sample size and events compared with the fixed design, in exchange for the chance to stop early for overwhelming efficacy. O'Brien-Fleming spending keeps early boundaries very conservative and the final boundary close to the fixed-design value, whereas Pocock spending spends more alpha early.

Sensitivity to a smaller true effect

Planning for exactly the observed effect is optimistic, because observed effects in published trials tend to be somewhat larger than the true effect. The table repeats the main design (three looks, O'Brien-Fleming spending, 90% power) for smaller true hazard ratios.

For context, this trial enrolled 455 participants.

Cross-check, upper boundaries: gsDesign 3.71, 2.511, 1.993 | rpact 3.71, 2.511, 1.993. Agreement between the two packages confirms the boundary calculation.

R code and output

suppressWarnings(suppressMessages({ library(gsDesign); library(rpact) }))
med_control <- 1.84615384615385          # control-arm median, months (converted from the posted unit)
hr          <- 0.45          # hazard ratio used for planning
lambdaC     <- log(2) / med_control
eta         <- 0.01               # dropout hazard per month (assumption)
acc_months  <- 24                 # accrual duration (assumption)
study_months<- 60                 # total study duration (assumption)

design <- function(k, sfu, beta, h = hr) gsSurv(k = k, test.type = 1, alpha = 0.025, beta = beta, sfu = sfu,
  lambdaC = lambdaC, hr = h, hr0 = 1, eta = eta, gamma = 1, R = acc_months, T = study_months, minfup = study_months - acc_months)

# Main design: 3 looks, Lan-DeMets O'Brien-Fleming spending, one-sided alpha 0.025, 90% power
x <- design(3, sfLDOF, 0.10)
cat(sprintf("N_TOTAL|%s\n", format(ceiling(sum(x$gamma * x$R)), big.mark = ",")))
for (i in 1:3) cat(sprintf("GS|%d|%.1f|%.0f|%.3f|%.5f|%.5f\n", i, x$T[i], x$n.I[i], x$upper$bound[i], pnorm(-x$upper$bound[i]), cumsum(x$upper$spend)[i]))
cat("\n"); print(gsBoundSummary(x))

# Comparison of designs
cmp <- list(list("Fixed design, one analysis", 1, sfLDOF), list("Two looks, O'Brien-Fleming", 2, sfLDOF),
            list("Three looks, O'Brien-Fleming", 3, sfLDOF), list("Three looks, Pocock", 3, sfLDPocock))
cat("\n")
for (b in c(0.20, 0.10)) for (d in cmp) {
  y <- design(d[[2]], d[[3]], b)
  cat(sprintf("DES|%s|%d|%.0f|%s|%.1f\n", d[[1]], round(100 * (1 - b)), tail(y$n.I, 1), format(ceiling(sum(y$gamma * y$R)), big.mark = ","), tail(y$T, 1)))
}

# Sensitivity: what if the true effect is smaller than the observed one? (3 looks, O'Brien-Fleming, 90% power)
cat("\n")
for (fr in c(1, 0.75, 0.5)) {
  y <- design(3, sfLDOF, 0.10, exp(log(hr) * fr))
  cat(sprintf("SENS|%.2f|%.3f|%.0f|%s\n", fr, exp(log(hr) * fr), tail(y$n.I, 1), format(ceiling(sum(y$gamma * y$R)), big.mark = ",")))
}

# Independent cross-check of the boundaries with rpact
r <- getDesignGroupSequential(kMax = 3, alpha = 0.025, beta = 0.10, sided = 1, typeOfDesign = "asOF", informationRates = x$timing)
cat(sprintf("\nCross-check, upper boundaries: gsDesign %s | rpact %s\n", paste(round(x$upper$bound, 3), collapse = ", "), paste(round(r$criticalValues, 3), collapse = ", ")))

Method: LachinFoulkes 
   Analysis               Value Efficacy
  IA 1: 33%                   Z   3.7103
      N: 34         p (1-sided)   0.0001
 Events: 23        ~HR at bound   0.2067
  Month: 12    P(Cross) if HR=1   0.0001
            P(Cross) if HR=0.45   0.0338
  IA 2: 67%                   Z   2.5114
      N: 58         p (1-sided)   0.0060
 Events: 45        ~HR at bound   0.4702
  Month: 20    P(Cross) if HR=1   0.0060
            P(Cross) if HR=0.45   0.5603
      Final                   Z   1.9930
      N: 70         p (1-sided)   0.0231
 Events: 67        ~HR at bound   0.6133
  Month: 60    P(Cross) if HR=1   0.0250
            P(Cross) if HR=0.45   0.9000



Cross-check, upper boundaries: gsDesign 3.71, 2.511, 1.993 | rpact 3.71, 2.511, 1.993

15. Analyses Reported by the Sponsor

The sponsor-reported primary analysis gives a hazard ratio of 0.45, a 95% confidence interval from 0.35 to 0.59, and p < 0.001, using the Stratified Log Rank Test. Those are the central inferential results to use when describing the primary comparison. The record does not flag a discrepancy between the sponsor’s analysis and the simple unadjusted recalculation from posted summary statistics.

A recalculation from summary data cannot reproduce every feature of a time-to-event analysis. It may not account for individual event times, censoring, stratification, or other details of the sponsor’s analysis. For that reason, the sponsor’s own analysis takes precedence if a discrepancy is identified. No such discrepancy is flagged for this result, but the reported method and estimate remain the appropriate reference for the trial’s primary analysis.

The same distinction applies to the overall survival comparisons: the registry reports its own Log Rank results, with each analysis tied to a data cut-off. Those results should be described as sponsor-reported analyses rather than treated as independent recalculations from group medians. A median alone does not provide enough information to reconstruct a hazard ratio or log-rank test.

16. Multiplicity, Missing Data and Analysis Populations

Multiplicity arises when a study evaluates multiple outcomes, time points, groups, or statistical tests. In general, conducting more tests increases the chance that at least one result will appear statistically notable by chance. The registry lists 24 outcome measures, 8 analyses, and 22 posted secondary outcomes. It does not report a family-wise error strategy, a hierarchical testing procedure, or another multiplicity adjustment. The secondary p-values should therefore be interpreted cautiously and in relation to the primary endpoint rather than treated as though each were the only test performed.

The primary PFS analysis is identified as using the intent-to-treat population. This label indicates the intended analysis population, but the registry record does not provide a detailed accounting of participants included in every analysis or describe all departures from assigned treatment. It also does not report the number of missing endpoint assessments or the reasons for missingness. The specific methods used to handle missing data are not reported in the registry record.

For a time-to-event endpoint, follow-up that ends before the event is recorded may be treated as censoring. The registry reports the PFS data cut-off and maximum follow-up, but does not describe the censoring distribution or provide enough information to evaluate censoring assumptions. Nor does it report sensitivity analyses for missing or censored observations. These omissions limit assessment of robustness beyond the stated estimate and confidence interval.

The original sample-size justification, planned number of events, interim-analysis arrangements, and complete statistical analysis plan are not reported in the registry record. The observed-effect planning illustrations are not evidence of the original design rationale. Without the full plan, it is not possible to establish from the registry alone how the analysis choices were prespecified or how the family of endpoints was intended to be interpreted.

17. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (19.0%), cardiac arrest (9.1%), cellulitis (9.1%), lower respiratory tract infection (9.1%), pneumonia respiratory syncytial viral (9.1%).

The adverse-event summary reports serious adverse events among 195 of 300 participants at risk in the pomalidomide plus low-dose dexamethasone group and 80 of 150 in the high-dose dexamethasone group. It also reports other adverse events among 291 of 300 and 143 of 150 participants at risk, respectively. These are descriptive counts for the groups and should be read with their reported denominators.

The registry also lists an HD-Dex / Pomalidomide group with 11 participants at risk, 4 with serious adverse events, 11 with other adverse events, and 8 deaths. The record does not give enough context to treat this small group as another randomized comparison arm or to infer why participants appear in it. The listed serious adverse-event terms include Pneumonia at 19.0%, and Cardiac arrest, Cellulitis, Lower respiratory tract infection, Pneumonia respiratory syncytial viral, and Respiratory tract infection each at 9.1%. The registry record does not clarify the denominator or overlap underlying each term percentage.

These summaries do not establish that a treatment caused an event, and deaths are not necessarily treatment-related. Comparative safety interpretation would require fuller information about event definitions, timing, severity, attribution, exposure, and follow-up. Those details are not all reported in the registry record.

18. What the Result Does, and Does Not, Mean

The posted primary results show a difference in progression-free survival summaries between the randomized groups during the reported follow-up. Median PFS was 15.7 weeks for pomalidomide plus low-dose dexamethasone and 8.0 weeks for high-dose dexamethasone. The reported hazard ratio was 0.45, with a 95% confidence interval from 0.35 to 0.59 and p < 0.001. This describes the estimated relative timing of progression or death under the trial’s analysis; it is not a guarantee about any participant’s outcome.

The overall survival analyses are also reported as favoring a lower estimated event hazard in the combination group, but they use distinct data cut-offs and follow-up periods. They should be interpreted separately from the primary PFS analysis. Secondary outcomes add descriptive evidence, yet their interpretation is constrained by the number of outcomes and the absence of a reported multiplicity strategy.

The results do not establish that every difference is caused by treatment, describe every aspect of safety, or show how results would apply beyond the studied population and trial conditions. Open-label treatment, unreported analysis details, and incomplete registry information about missing-data handling and multiplicity are relevant when judging the strength and scope of conclusions. Statistical significance is not the same as clinical importance, and neither a hazard ratio nor a p-value provides a complete account of benefits, harms, or individual experience.

The trial answers a comparative statistical question in the enrolled population under the reported methods and follow-up. It does not answer questions about other treatment regimens, other populations, or outcomes not reported in the registry. Interpreting the estimates alongside the endpoint definitions, confidence intervals, follow-up windows, and safety reporting gives a more complete account than relying on a single number.

19. Why This Trial Matters Statistically

This trial illustrates why time-to-event results need more than one summary. The median PFS describes a central point in the event-time distribution, while the hazard ratio compares event hazards across follow-up. Together they offer different views of the randomized comparison. Their interpretation still depends on follow-up, censoring, endpoint definition, and the analysis method.

It also shows the value of attaching every estimate to its data cut-off. The primary PFS analysis and the successive overall survival analyses use different follow-up windows. The later survival reports accumulate information from the same trial; they should not be mistaken for independent confirmations. Confidence intervals make the uncertainty around each estimate visible, while p-values address a different question about compatibility with a null hypothesis.

The record also highlights a common distinction between a trial’s original design and retrospective planning illustrations. The original sample-size justification is not reported, whereas the posted illustrations use fractions of the observed effect and stated planning assumptions. Those illustrations can help readers understand how event requirements respond to effect size, but they do not recover the trial’s original planning rationale or its achieved power.

Finally, the number of secondary outcomes makes multiplicity important. A clear primary result does not automatically make every secondary result confirmatory. Transparent reporting of prespecification, missing-data handling, and multiplicity methods would help readers judge how strongly secondary findings support the overall interpretation. The registry record gives a substantial amount of endpoint information, but leaves these methodological questions unresolved.

20. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The trial was open-label, so participants and study personnel were not masked to assigned treatment. The registry describes independent adjudication for progression, which is relevant to the primary endpoint, but does not report further details about masking of adjudicators or other safeguards against assessment bias. The registry record also does not report allocation-concealment procedures.

Several analysis details are unavailable in the registry record. These include the original sample-size justification, the complete statistical analysis plan, planned interim analyses, the factors used for stratification in the primary test, and the handling of missing endpoint data. The record does not describe proportional-hazards checks or provide detailed censoring information. These gaps prevent a full evaluation of some assumptions and analysis decisions.

The primary PFS result uses follow-up through 07 September 2012, with maximum PFS follow-up of 57 weeks. The overall survival analyses use later cut-offs, including the final dataset cut-off of 29 August 2017. The estimates therefore reflect different stages of follow-up and should not be compared as if they were calculated from identical data.

There are also limitations in interpreting the safety summary. The registry reports counts and selected serious-event terms, but does not provide all details needed to assess event timing, attribution, exposure-adjusted comparisons, or the overlap and denominators for the listed term percentages. The additional HD-Dex / Pomalidomide safety group is reported separately, but its relationship to the randomized groups is not explained in the adverse-event summary.

Finally, the registry lists multiple secondary outcomes without reporting a multiplicity adjustment strategy. This limits the confirmatory interpretation of secondary p-values. These limitations do not negate the posted estimates, but they define the scope of what can be concluded from the registry record.

21. Related Tutorials

22. Related Statistical Calculators

23. Sources

• ClinicalTrials.gov: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study — NCT01311687.
• Registry record last updated 2018-10-24; status last verified 2018-09.
• Results first posted 2014-04-30.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

24. Record Summary

The registry record describes a completed, randomized, open-label phase 3 parallel-group trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Enrollment was 455. The primary endpoint was progression-free survival in the intent-to-treat population, analyzed through 07 September 2012.

The reported primary hazard ratio was 0.45, with a 95% confidence interval from 0.35 to 0.59 and p < 0.001. Median PFS was 15.7 weeks in the combination group and 8.0 weeks in the high-dose dexamethasone group. Overall survival results were reported at multiple data cut-offs, alongside response and safety outcomes.

The registry does not report the full analysis plan, original sample-size justification, multiplicity strategy, or detailed missing-data methods. These omissions are important when assessing the scope and certainty of secondary findings and the trial’s analysis assumptions.